The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia|
- Ki-67 [ Time Frame: Two weeks ] [ Designated as safety issue: No ]Biomarker. Change in Ki-67 staining between pre- and on-therapy biopsies in patients with Barrett's esophagus.
|Study Start Date:||June 2006|
|Study Completion Date:||September 2009|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
sorafenib 2 tablets by mouth
2 tablets with water by mouth twice a day for two weeks.
Other Name: Sorafenib
To characterize the effects of sorafenib on specific molecular markers in patients with Barrett's esophagus and high grade intraepithelial neoplasia (HGIN) or carcinoma in situ (CIS).
|United States, Illinois|
|University of Chicago|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||Ezra Cohen, MD||University of Chicago|